MDxHealth, Inc. and PLUS Diagnostics Enter U.S. Marketing Agreement for ConfirmMDx™ for Prostate Cancer  
4/26/2012 10:28:20 AM

IRVINE, Calif., & LIEGE, Belgium--(BUSINESS WIRE)--Regulatory News: MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to support cancer treatment, and PLUS Diagnostics today announced that they have entered into an agreement to co-promote MDxHealth’s ConfirmMDx™ for Prostate Cancer test in the United States.